In other human solid tumors such as colorectal cancer, head and neck squamous cell carcinoma, nasopharyngeal cancer, glioblastoma, and pancreatic cancer, the overexpression of EGFR was observed and EGFR-targeting agents were approved by the FDA for the treatment of these tumors [20]. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.